Join BioGenCell for a virtual key opinion leader (KOL) event featuring Richard J. Powell, MD (Director of the Dartmouth Health Heart and Vascular Center), who will join company management to discuss the unmet need and current treatment landscape for patients suffering from peripheral arterial disease (PAD) with chronic limb-threatening ischemia (CLTI) who do not have the option of further revascularization treatment.

The event will highlight results from BioGenCell’s Phase 2 Clinical Trial evaluating BGC101 (Enriched Endothelial Progenitor Cells) for the treatment of CLTI, presented at the VEITHsymposium in New York from November 18-20, 2025. BioGenCell is developing an autologous cell therapy for CLTI, aiming to offer a minimally invasive alternative for patients with no remaining surgical or endovascular options.

A live question and answer session will follow the formal presentations.